The flu drug most Americans have never heard of is called Xofluza, and it has been the most-prescribed influenza treatment in Japan since shortly after its launch in 2018. Developed by Japanese pharmaceutical company Shionogi & Co., Ltd., Xofluza (baloxavir marboxil) is a single-dose oral antiviral that represents the first new class of flu medication in nearly 20 years. Unlike Tamiflu, which requires ten doses over five days, Xofluza works with just one pill — and it attacks the influenza virus through an entirely different mechanism, stopping viral RNA replication rather than merely slowing viral spread.
For readers of a brain health and dementia care site, this matters more than you might think. Influenza poses serious risks to older adults and people with neurological conditions, and prolonged illness can worsen cognitive symptoms, trigger delirium, and lead to hospitalizations that accelerate decline. A flu treatment that cuts viral shedding in half and requires only a single dose could be a meaningful tool for caregivers managing complex medication regimens. This article covers how Xofluza works, what the clinical trials actually showed, how it compares to Tamiflu in practice, who should and should not take it, and what it costs in the United States today.
Table of Contents
- What Is the Flu Drug Japanese Doctors Prescribe That Most Americans Don’t Know About?
- What the Clinical Trials Actually Showed — And Where Xofluza Falls Short
- Why a Single-Dose Flu Treatment Matters for Dementia Caregiving
- Xofluza vs. Tamiflu — A Head-to-Head Comparison for Older Adults
- Cost, Access, and the Barriers That Keep Xofluza Under the Radar
- Using Xofluza as Prevention After Flu Exposure
- What Comes Next for Xofluza and Flu Treatment
- Conclusion
- Frequently Asked Questions
What Is the Flu Drug Japanese Doctors Prescribe That Most Americans Don’t Know About?
Xofluza earned its first global approval in Japan in February 2018 for the treatment of influenza A and B. Within months, it became the dominant flu treatment in the country, overtaking Tamiflu in prescriptions. The drug arrived in the United States later that year, receiving FDA approval in October 2018 for patients aged 12 and older with acute uncomplicated influenza. Since then, the FDA has expanded its approved uses twice — first in October 2019 to include high-risk patients, and again in November 2020 for post-exposure prophylaxis, meaning it can be taken to prevent the flu after known contact with an infected person. As of August 2022, the prophylaxis indication extends down to children as young as five. Xofluza is now approved in more than 80 countries worldwide. What makes Xofluza genuinely novel is its mechanism of action.
It is a cap-dependent endonuclease inhibitor, which is a technical way of saying it targets a specific enzyme the influenza virus needs to copy its genetic material. Tamiflu and its relatives are neuraminidase inhibitors — they block the virus from escaping infected cells, slowing its spread but not stopping replication directly. Xofluza essentially shuts down the virus’s ability to reproduce at all. In clinical studies, this translated to a dramatic reduction in the amount of virus circulating in a patient’s body within 24 hours of taking a single dose, compared to roughly 72 hours for Tamiflu. The practical difference is hard to overstate for caregivers. Administering Tamiflu twice a day for five days to an elderly person with dementia — someone who may resist taking medication, forget doses, or struggle with swallowing — is a real challenge. A single dose of Xofluza eliminates that problem entirely. You give one pill, and the treatment is done.
What the Clinical Trials Actually Showed — And Where Xofluza Falls Short
The pivotal data on Xofluza comes from two Phase 3 trials known as CAPSTONE-1 and CAPSTONE-2. In the CAPSTONE-1 trial, which enrolled otherwise healthy patients with flu, the median time to symptom relief was 54 hours for those taking Xofluza compared to 80 hours for placebo — roughly a full day faster. Viral shedding, a measure of how long someone is contagious, dropped to a median of 48 hours with Xofluza versus 96 hours for both placebo and Tamiflu. that last number is worth pausing on: Xofluza cut the period of contagiousness in half compared to Tamiflu, even though it shortened symptoms by about the same amount. The CAPSTONE-2 trial focused on high-risk patients, including older adults and those with chronic medical conditions — a population much closer to the readers of this site. Here, Xofluza reduced symptom duration to a median of 73.2 hours versus 102.3 hours for placebo, an improvement of about 29 hours.
For post-exposure prophylaxis, the numbers were striking: only 1 percent of people who took Xofluza after being exposed to the flu went on to develop the illness, compared to 13 percent on placebo. However, there is a significant caveat. Xofluza has a resistance problem, particularly in younger patients. Treatment-emergent resistance — meaning the virus mutated to evade the drug during the course of treatment — was observed in approximately 7 percent of patients aged 12 and older, 16 percent of children ages 5 to 12, and a troubling 40 percent of children under five. This is one reason Xofluza is not approved for treatment in children under five. For older adults, the 7 percent resistance rate is lower but not negligible, and clinicians should be aware of it, especially in institutional settings like memory care facilities where flu can spread rapidly among residents.
Why a Single-Dose Flu Treatment Matters for Dementia Caregiving
Anyone who has cared for a person with moderate or advanced dementia knows that medication adherence is one of the most persistent daily struggles. A five-day course of Tamiflu, taken twice daily, means ten separate opportunities for a missed dose, a refused pill, or a confused interaction. In a memory care facility, it means ten rounds of staff time, documentation, and potential conflict with a resident who does not understand why they need to swallow something. Xofluza collapses all of that into a single moment. Consider a common scenario: a resident in a memory care unit develops flu symptoms after a visitor unknowingly brings the virus in. The facility physician confirms influenza with a rapid test.
With Tamiflu, the staff must now manage a twice-daily medication for five days in a patient who already takes multiple other pills, may have swallowing difficulties, and becomes agitated during medication passes. With Xofluza, the treatment is a single weight-based dose — one pill, observed to be swallowed, and the treatment is complete. The staff can then focus on supportive care, hydration, and monitoring. Beyond adherence, there is the issue of viral shedding. In congregate living settings, the length of time a sick person remains contagious directly affects how many other residents get infected. Xofluza’s ability to cut viral shedding time in half compared to Tamiflu — from a median of 96 hours down to 48 — could meaningfully reduce the scope of an outbreak. For a population where every hospitalization carries the risk of accelerated cognitive decline, preventing secondary infections is not a minor consideration.
Xofluza vs. Tamiflu — A Head-to-Head Comparison for Older Adults
Both Xofluza and Tamiflu are effective flu antivirals, but they differ in ways that matter for clinical decision-making. In terms of symptom duration, the two drugs perform roughly the same — both shorten illness by about a day compared to placebo. The real differences show up in dosing convenience, viral clearance speed, and side effect profiles. Tamiflu requires 10 doses over five days. Xofluza requires one. Tamiflu begins meaningfully reducing viral load at around 72 hours. Xofluza achieves significant viral reduction within 24 hours.
On the side effect front, Tamiflu is well known for causing nausea and vomiting, which can be particularly problematic in elderly patients who may already have poor appetite or be at risk for dehydration. Xofluza’s most commonly reported side effects — diarrhea, bronchitis, nausea, and headache — tend to be milder and less gastrointestinal in nature, though individual responses vary. The tradeoff is availability and familiarity. Tamiflu has been around since 1999 and is available as a generic, making it significantly cheaper and more widely stocked in pharmacies. Many physicians are more comfortable prescribing it simply because they have decades of experience with the drug. Tamiflu can also be used in younger children, which is not relevant for dementia caregiving but matters in multigenerational households. And Tamiflu does not carry the same resistance concerns that have been documented with Xofluza. For caregivers weighing these options with a physician, the conversation should center on the specific patient — their ability to take multiple doses, their risk for gastrointestinal side effects, and whether the setting demands faster viral clearance to protect others.
Cost, Access, and the Barriers That Keep Xofluza Under the Radar
One of the main reasons Xofluza remains relatively obscure in the United States, despite being the go-to flu drug in Japan, is cost. The retail price for a single dose runs between $161 and $219, a significant expense compared to generic Tamiflu. For patients without insurance or with high-deductible plans, that price tag alone can end the conversation before it starts. There is some relief on the horizon. In October 2025, Genentech launched a direct-to-patient program offering Xofluza for $50 cash pay — roughly 70 percent below the list price. This makes it more accessible, though $50 for a single pill is still more than many people expect to pay for a flu treatment. Insurance coverage varies widely; some plans cover it without issue, while others require prior authorization or steer patients toward generic Tamiflu.
For Medicare beneficiaries, coverage depends on the specific Part D plan. The other barrier is awareness. Many American physicians simply do not think of Xofluza when they reach for a prescription pad during flu season. Tamiflu is deeply embedded in clinical training and habit. Shionogi retains exclusive rights to market Xofluza in Japan and Taiwan, while Roche and its subsidiary Genentech handle the rest of the world. Genentech has increased marketing efforts in recent years, but the drug still lacks the name recognition that Tamiflu built over two decades. If you or someone you care for is in a high-risk group, it is worth specifically asking a doctor whether Xofluza is appropriate — do not assume it will be offered unprompted.
Using Xofluza as Prevention After Flu Exposure
One of Xofluza’s most underused applications is post-exposure prophylaxis — taking the drug after known contact with someone who has the flu, before symptoms develop. The clinical data here is compelling: only 1 percent of people who took Xofluza after exposure went on to develop influenza, compared to 13 percent on placebo. For a caregiver who has just learned that their care recipient was exposed to the flu during an adult day program or a family visit, a single prophylactic dose of Xofluza could prevent the illness entirely.
This is particularly relevant in memory care settings during outbreaks. When one resident tests positive, facilities face a race to contain the spread. Prophylactic Xofluza for exposed but asymptomatic residents, administered as a single dose rather than a multi-day regimen, could be a practical outbreak management tool. Caregivers should discuss this option with facility medical directors before flu season, not after an outbreak is already underway.
What Comes Next for Xofluza and Flu Treatment
Xofluza’s core patent does not expire until April 2036, with potential extensions reaching approximately 2040. That means this drug will remain brand-name only for another decade at minimum, which limits how quickly it can become the default flu treatment the way generic Tamiflu has. Global sales reached approximately $685 million in 2023, reflecting growing but still modest adoption outside Japan.
The longer-term question is whether combination therapies — using Xofluza’s rapid viral suppression alongside a neuraminidase inhibitor — could offer even better outcomes for the most vulnerable patients. Early research is exploring this, though no combination regimen is currently approved. For the dementia care community, the more immediate hope is simply broader awareness: a drug that works in a single dose, clears the virus faster than anything else available, and has a strong safety profile in older adults deserves a much larger role in how we protect cognitively vulnerable people during flu season.
Conclusion
Xofluza represents a genuine advance in influenza treatment — the first new class of flu drug in two decades, requiring just one pill instead of ten, and clearing viral load twice as fast as Tamiflu. For caregivers managing dementia, where medication adherence is a constant battle and every hospitalization carries cognitive risk, it addresses real problems that Tamiflu does not. The clinical data from the CAPSTONE trials, the post-exposure prevention numbers, and the favorable side effect profile all support its use in older and high-risk adults. The barriers to wider adoption are real but not insurmountable.
Cost remains higher than generic alternatives, though new patient assistance programs are narrowing the gap. Physician awareness is growing but still lags behind Japan, where the drug has been the standard of care for years. If you are a caregiver, bring up Xofluza by name at your next doctor’s appointment or your care recipient’s next annual wellness visit — ideally before flu season starts. Do not wait until someone is already sick to learn about the options.
Frequently Asked Questions
Is Xofluza better than Tamiflu?
Xofluza clears the virus from the body about twice as fast as Tamiflu and requires only a single dose instead of ten doses over five days. However, symptom duration improves by roughly the same amount with both drugs. The choice depends on individual factors including cost, insurance coverage, and the patient’s ability to complete a multi-day regimen.
Can someone with dementia take Xofluza?
Yes. Xofluza is approved for adults with influenza and does not carry specific contraindications for people with dementia or other neurological conditions. The single-dose format is actually a significant advantage for patients who have difficulty with medication adherence. As with any medication, consult the prescribing physician about potential interactions with existing medications.
How much does Xofluza cost without insurance?
The retail price ranges from $161 to $219 for a single dose. However, Genentech’s direct-to-patient program offers it for $50 cash pay, which is a substantial reduction. Insurance coverage varies by plan.
Can Xofluza be used to prevent the flu after exposure?
Yes. The FDA approved Xofluza for post-exposure prophylaxis in people aged 12 and older in November 2020, and expanded this to ages 5 and up in August 2022. In clinical trials, only 1 percent of people who took Xofluza after exposure developed the flu, compared to 13 percent on placebo.
Does the flu virus develop resistance to Xofluza?
Resistance has been observed, particularly in younger patients. In clinical trials, treatment-emergent resistance occurred in about 7 percent of patients aged 12 and older, 16 percent of children ages 5 to 12, and 40 percent of children under 5. For adult and elderly patients, the resistance rate is relatively low but should be factored into treatment decisions, especially in outbreak settings.
Is Xofluza available as a generic?
No. Xofluza’s core patent runs until April 2036, with possible extensions to around 2040. There will be no generic version available for at least a decade.
